Abnormal glucose tolerance in transfusion-dependent beta-thalassemic patients.
OBJECTIVE
To study the prevalence of and risk factors for abnormal glucose tolerance in transfusion-dependent beta-thalassemic patients.


METHODS
A total of 89 transfusion-dependent beta-thalassemic patients were interviewed. Diabetes was previously diagnosed in 14 of them. In the remaining 75 patients, 68 participated in an oral glucose tolerance test. Potential risk factors were identified using the independent t test, chi2 test, and Fisher's exact test. Logistic regression analysis was used to select the independent risk factors that best predicted abnormal glucose tolerance A two-tailed P value of <0.05 was considered to be statistically significant.


RESULTS
The prevalence of impaired glucose tolerance was 8.5% (7 of 82) and that of diabetes was 19.5% (16 of 82). Presentation with diabetic ketoacidosis was 31.1% (5 of 16). The risk factors for abnormal glucose tolerance found in transfusion-dependent beta-thalassemic patients were serum ferritin concentration and hepatitis C infection.


CONCLUSIONS
The interaction of iron overload and hepatitis C infection worsened the prognosis of thalassemic patients. Aggressive iron-chelation therapy as well as prevention and treatment of hepatitis C infection should be mandatory in managing glucose homeostasis in transfusion-dependent beta-thalassemic patients in Taiwan.
Chern
J P
JP
Department of Family Medicine, Tao-Yuan Hospital, Taiwan, Republic of China.
Lin
K H
KH
Lu
M Y
MY
Lin
D T
DT
Lin
K S
KS
Chen
J D
JD
Fu
C C
CC
D000293:Adolescent; D000328:Adult; D001803:Blood Transfusion; D002648:Child; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D005293:Ferritins / Q000097:blood; D018149:Glucose Intolerance / Q000453:epidemiology*; D006509:Hepatitis B / Q000453:epidemiology; D006526:Hepatitis C / Q000453:epidemiology; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D008297:Male; D010349:Patient Compliance; D015995:Prevalence; D012307:Risk Factors; D013624:Taiwan; D017086:beta-Thalassemia / Q000097:blood* / Q000150:complications / Q000628:therapy*
D007502:Iron Chelating Agents; D005293:Ferritins